Estimating incidence and attributable length of stay of healthcare-associated infections-Modeling the Swiss point-prevalence survey.


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
08 2022
Historique:
pubmed: 6 8 2021
medline: 4 8 2022
entrez: 5 8 2021
Statut: ppublish

Résumé

In 2017, a point-prevalence survey was conducted with 12,931 patients in 96 hospitals across Switzerland as part of the national strategy to prevent healthcare-associated infections (HAIs). We present novel statistical methods to assess incidence proportions of HAI and attributable length-of-stay (LOS) in point-prevalence surveys. Follow-up data were collected for a subsample of patients and were used to impute follow-up data for all remaining patients. We used weights to correct length bias in logistic regression and multistate analyses. Methods were also tested in simulation studies. The estimated incidence proportion of HAIs during hospital stay and not present at admission was 2.3% (95% confidence intervals [CI], 2.1-2.6), the most common type being lower respiratory tract infections (0.8%; 95% CI, 0.6-1.0). Incidence proportion was highest in patients with a rapidly fatal McCabe score (7.8%; 95% CI, 5.7-10.4). The attributable LOS for all HAI was 6.4 days (95% CI, 5.6-7.3) and highest for surgical site infections (7.1 days, 95% CI, 5.2-9.0). It was longest in the age group of 18-44 years (9.0 days; 95% CI, 5.4-12.6). Risk-factor analysis revealed that McCabe score had no effect on the discharge hazard after infection (hazard ratio [HR], 1.21; 95% CI, 0.89-1.63). Instead, it only influenced the infection hazard (HR, 1.84; 95% CI, 1.39-2.43) and the discharge hazard prior to infection (HR, 0.73; 95% CI, 0.66-0.82). In point-prevalence surveys with limited follow-up data, imputation and weighting can be used to estimate incidence proportions and attributable LOS that would otherwise require complete follow-up data.

Identifiants

pubmed: 34348807
pii: S0899823X21002956
doi: 10.1017/ice.2021.295
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1022-1031

Auteurs

Sam Doerken (S)

Institute of Medical Biometry and Statistics, Division Methods in Clinical Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Freiburg Center for Data Analysis and Modeling, Freiburg, Germany.

Aliki Metsini (A)

Swissnoso, Swiss Center for Infection Prevention, Bern, Switzerland.
Cantonal physician office, State of Geneva, Geneva, Switzerland.

Sabina Buyet (S)

Spital Bülach AG, Bülach, Switzerland.

Aline Wolfensberger (A)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital and University of Zurich, Zurich, Switzerland.

Walter Zingg (W)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital and University of Zurich, Zurich, Switzerland.

Martin Wolkewitz (M)

Institute of Medical Biometry and Statistics, Division Methods in Clinical Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Freiburg Center for Data Analysis and Modeling, Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH